These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

471 related articles for article (PubMed ID: 27536686)

  • 1. The Clinical Presentation and Management of Systemic Light-Chain Amyloidosis in China.
    Huang XH; Liu ZH
    Kidney Dis (Basel); 2016 Apr; 2(1):1-9. PubMed ID: 27536686
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The Prevalence and Management of Systemic Amyloidosis in Western Countries.
    Nienhuis HL; Bijzet J; Hazenberg BP
    Kidney Dis (Basel); 2016 Apr; 2(1):10-9. PubMed ID: 27536687
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Treatment of AL amyloidosis in 2012; the benefit of new drugs (bortezomib, thalidomide, and lenalidomide). Summary of published clinical trials].
    Adam Z; Sčudla V; Krejčí M; Cermáková Z; Pour L; Král Z
    Vnitr Lek; 2013 Jan; 59(1):37-58. PubMed ID: 23428001
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Light chain (AL) amyloidosis: update on diagnosis and management.
    Rosenzweig M; Landau H
    J Hematol Oncol; 2011 Nov; 4():47. PubMed ID: 22100031
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Current and emerging views and treatments of systemic immunoglobulin light-chain (Al) amyloidosis.
    Comenzo RL
    Contrib Nephrol; 2007; 153():195-210. PubMed ID: 17075231
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Induction bortezomib in Al amyloidosis followed by high dose melphalan and autologous stem cell transplantation: a single institution retrospective study.
    Scott EC; Heitner SB; Dibb W; Meyers G; Smith SD; Abar F; Kovacsovics T; Perez-Avraham G; Stentz A; Frires R; Dibb J; Maziarz RT
    Clin Lymphoma Myeloma Leuk; 2014 Oct; 14(5):424-430.e1. PubMed ID: 24650974
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Light Chain Amyloidosis: an Update for Treatment].
    Shen KN; Li J
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2015 Jun; 23(3):910-4. PubMed ID: 26117060
    [TBL] [Abstract][Full Text] [Related]  

  • 8. High-dose melphalan with autologous stem cell transplantation after VAD induction chemotherapy for treatment of amyloid light chain amyloidosis: a single centre prospective phase II study.
    Perz JB; Schonland SO; Hundemer M; Kristen AV; Dengler TJ; Zeier M; Linke RP; Ho AD; Goldschmidt H
    Br J Haematol; 2004 Dec; 127(5):543-51. PubMed ID: 15566357
    [TBL] [Abstract][Full Text] [Related]  

  • 9. New and developing therapies for AL amyloidosis.
    Zumbo G; Sadeghi-Alavijeh O; Hawkins PN; Fontana M
    Expert Opin Pharmacother; 2017 Feb; 18(2):139-149. PubMed ID: 28002971
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Light-chain amyloidosis: SCT, novel agents and beyond.
    Rosenzweig M; Giralt S; Landau H
    Bone Marrow Transplant; 2013 Aug; 48(8):1022-7. PubMed ID: 23103675
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Treatment of primary systemic amyloidosis (AL): role of intensive and standard therapy.
    Sher T; Hayman SR; Gertz MA
    Clin Adv Hematol Oncol; 2012 Oct; 10(10):644-51. PubMed ID: 23187770
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Heart transplantation and the subsequent treatment of AL amyloidosis].
    Adam Z; Krejčí J; Krejčí M; Němec P; Spinarová L; Zampachová V; Cermáková Z; Pika T; Pour L; Kořístek Z; Tomíška M; Szturz P; Král Z; Mayer J
    Vnitr Lek; 2013 Feb; 59(2):136-47. PubMed ID: 23461404
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Managing systemic light-chain amyloidosis.
    Comenzo RL
    J Natl Compr Canc Netw; 2007 Feb; 5(2):179-87. PubMed ID: 17335687
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Current and Emerging Immunotherapies for Systemic AL Amyloidosis.
    Moreno V; Saba L; Tama-Shekan S; Chaulagain CP
    Discov Med; 2024 Sep; 36(188):1761-1771. PubMed ID: 39327239
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Renal disorders associated with monoclonal gammopathies: diagnostic and therapeutic progress].
    Bridoux F; Delbes S; Sirac C; Pourreau F; Puyade M; Desport E; Jaccard A; Fermand JP; Touchard G
    Presse Med; 2012 Mar; 41(3 Pt 1):276-89. PubMed ID: 22244725
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Autologous stem cell transplantation vs bortezomib based chemotheraphy for the first-line treatment of systemic light chain amyloidosis in the UK.
    Sharpley FA; Manwani R; Petrie A; Mahmood S; Sachchithanantham S; Lachmann HJ; Martinez De Azcona Naharro A; Gillmore JD; Whelan CJ; Fontana M; Cohen O; Hawkins PN; Wechalekar AD
    Eur J Haematol; 2021 Apr; 106(4):537-545. PubMed ID: 33460466
    [TBL] [Abstract][Full Text] [Related]  

  • 17. New insights and modern treatment of AL amyloidosis.
    Chaulagain CP; Comenzo RL
    Curr Hematol Malig Rep; 2013 Dec; 8(4):291-8. PubMed ID: 24026941
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Al amyloidosis.
    Desport E; Bridoux F; Sirac C; Delbes S; Bender S; Fernandez B; Quellard N; Lacombe C; Goujon JM; Lavergne D; Abraham J; Touchard G; Fermand JP; Jaccard A;
    Orphanet J Rare Dis; 2012 Aug; 7():54. PubMed ID: 22909024
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pre-transplantation novel agent induction predicts progression-free survival for patients with immunoglobulin light-chain amyloidosis undergoing high-dose melphalan and autologous stem cell transplantation.
    Cowan AJ; Klippel ZK; Stevenson PA; Hyun TS; Tuazon S; Becker PS; Green DJ; Holmberg LA; Coffey DG; Gopal AK; Libby EN
    Amyloid; 2016 Dec; 23(4):254-259. PubMed ID: 27879147
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Complete remission of both immunoglobulin light chain amyloidosis and psoriasis after autologous hematopoietic stem cell transplantation: A case report.
    Chen W; Ren G; Zuo K; Huang X
    Medicine (Baltimore); 2018 Dec; 97(50):e13589. PubMed ID: 30558027
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 24.